Arena Pharmaceuticals, Inc. (ARNA) financial statements (2021 and earlier)

Company profile

Business Address 6154 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,1041,1681,1718007407841,006
Cash and cash equivalents220460550190243171200
Short-term investments884708620610496613806
Receivables   0222
Contract with customer, asset     11
Other undisclosed current assets35343330191919
Total current assets:1,1391,2021,2048307608061,029
Noncurrent Assets
Property, plant and equipment22232425252423
Long-term investments and receivables 3395217371390216
Long-term investments 3395217371390216
Other noncurrent assets29171718182217
Total noncurrent assets:5173136260414436256
TOTAL ASSETS:1,1911,2761,3401,0901,1741,2421,285
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3527182525149
Accounts payable128213642
Accrued liabilities5454500
Employee-related liabilities19151181497
Other undisclosed current liabilities23252419192319
Total current liabilities:58524244453728
Noncurrent Liabilities
Liabilities, other than long-term debt1111121212128
Other liabilities1111121212128
Other undisclosed noncurrent liabilities41   46  
Total noncurrent liabilities:5211121258128
Total liabilities:1106354571034936
Stockholders' equity
Stockholders' equity attributable to parent1,0801,1701,2439881,0711,1461,201
Common stock0000000
Additional paid in capital2,5872,5542,5282,1922,1732,1592,141
Accumulated other comprehensive income1230111
Accumulated deficit(1,508)(1,386)(1,288)(1,203)(1,103)(1,015)(942)
Total stockholders' equity:1,0801,1701,2439881,0711,1461,201
Other undisclosed liabilities and equity 424345 4748
TOTAL LIABILITIES AND EQUITY:1,1911,2761,3401,0901,1741,2421,285

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues00 0311
Cost of revenue
(Other undisclosed Cost of revenue)
    0  
Gross profit:00 0311
Operating expenses(135)(99)(88)(105)(97)(81)(70)
Operating loss:(135)(99)(88)(105)(94)(79)(69)
Nonoperating income13135667
Investment income, nonoperating14235678
Other nonoperating income0111111
Interest and debt expense(1)(1)(1)(1)(1)(1)(1)
Loss from continuing operations before equity method investments, income taxes:(123)(99)(86)(101)(89)(74)(63)
Other undisclosed income from continuing operations before income taxes1111111
Net loss available to common stockholders, diluted:(122)(97)(85)(100)(88)(73)(61)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(122)(97)(85)(100)(88)(73)(61)
Other comprehensive income (loss)(1)(1)2(1)(0)01
Other undisclosed comprehensive loss    (0)  
Comprehensive loss:(123)(99)(82)(101)(88)(73)(61)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent000(0)0(0)0
Comprehensive loss, net of tax, attributable to parent:(123)(99)(82)(101)(88)(73)(61)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: